Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(2 months from now) | |
US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(3 months from now) | |
US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(3 months from now) | |
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(8 months from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of schizophrenia
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(6 months from now) | |
US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(6 months from now) | |
US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(6 months from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(2 months from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7923536 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(2 months from now) | |
US8314156 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(2 months from now) | |
US8138229 (Pediatric) | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(2 months from now) | |
US7820788 | BRISTOL MYERS SQUIBB CO | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(2 months from now) | |
US8207215 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(8 months from now) | |
US8541463 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(8 months from now) | |
US8377982 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(8 months from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating ocular pain; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A met...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8992952 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(4 months from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9370629 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(a month from now) | |
US8991387 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(a month from now) | |
US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(4 months from now) | |
US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(7 months from now) |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(5 months from now) | |
US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(6 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(6 months from now) |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
Market Authorisation Date: 14 September, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) | |
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(4 months from now) |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(5 months from now) |
Drugs and Companies using RETAPAMULIN ingredient
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: OINTMENT;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(5 months from now) |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8802137 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(13 days from now) | |
US9827317 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(13 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination anti...
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(a month ago) | |
US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(a month ago) | |
US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(a month ago) | |
US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(a month ago) |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8920377 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9833573 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 10 August, 2012
Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(18 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 26, 2030 |
New Product (NP) | Sep 26, 2026 |
Pediatric Exclusivity (PED) | Mar 26, 2027 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 26 September, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Nov 5, 2023 |
M (M) | May 9, 2025 |
Pediatric Exclusivity (PED) | Nov 9, 2025 |
Drugs and Companies using TICAGRELOR ingredient
Market Authorisation Date: 20 July, 2011
Treatment: Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and ...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(20 days from now) | |
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(20 days from now) | |
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(20 days from now) | |
US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(20 days from now) | |
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(a month from now) |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(a month from now) |
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(5 months from now) |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11278544 | NALPROPION | Compositions for affecting weight loss |
Apr, 2024
(26 days from now) | |
US7462626 | NALPROPION | Compositions for affecting weight loss |
Jul, 2024
(3 months from now) | |
US8815889 | NALPROPION | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(3 months from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8541393 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(7 months from now) | |
US9339036 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 15, 2028 |
Generating Antibiotic Incentives Now (GAIN) | Nov 15, 2033 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 2032-11-15
Market Authorisation Date: 15 November, 2023
Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter
Dosage: SOLUTION;N/A
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(20 days from now) | |
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(20 days from now) |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(20 days from now) |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Oct 7, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: NA
Dosage: INSERT;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(5 months from now) |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: NA
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(8 months from now) |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(a month from now) |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10398707 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(8 days from now) |
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7468390 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
May, 2024
(2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(5 months from now) | |
US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7964202 | GALDERMA LABS LP | Method for treatment of common acne |
Sep, 2024
(5 months from now) |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(a month from now) |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10130580 | ARBOR PHARMS LLC | Taste-masked pharmaceutical compositions |
Apr, 2024
(24 days from now) |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(7 months from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8603514 | MITSUBISHI HOLDINGS | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(8 days from now) |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 22 November, 2019
Treatment: NA
Dosage: FILM;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(20 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Apr 30, 2024 |
M (M) | May 8, 2026 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(6 months from now) | |
US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(6 months from now) | |
US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(6 months from now) | |
US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(8 months from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(9 months from now) | |
US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(9 months from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET;BUCCAL, SUBLINGUAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9320862 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Nov, 2024
(7 months from now) |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 02 August, 2016
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(5 months from now) | |
US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(5 months from now) |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 26 October, 2004
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: TABLET, CHEWABLE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(a month from now) | |
US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-03-10
Market Authorisation Date: 10 March, 2021
Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6949571 | EISAI INC | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
Jun, 2024
(2 months from now) |
Drugs and Companies using PERAMPANEL ingredient
Market Authorisation Date: 22 October, 2012
Treatment: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(2 months ago) | |
US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 2023-11-21
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8158645 | NOVARTIS | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(8 months from now) |
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 October, 2007
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7947295 | NOVARTIS | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(2 months from now) |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(4 months from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(4 months from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6975902 | THE MEDICINES CO | Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof |
Apr, 2024
(6 days from now) |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(8 days from now) |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 12 October, 2007
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(4 months from now) |
Drugs and Companies using IXABEPILONE ingredient
Market Authorisation Date: 16 October, 2007
Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(7 months from now) | |
US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(7 months from now) | |
US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(7 months from now) | |
US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(7 months from now) | |
US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(7 months from now) | |
US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(7 months from now) | |
USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(7 months from now) |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2007
Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobio...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8603514 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(8 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: NA
Dosage: FILM;SUBLINGUAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(a month from now) |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of stimulating hair growth; Method of increasing hair growth
Dosage: SOLUTION/DROPS;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(4 months from now) |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2010
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(6 months from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(2 months ago) | |
US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(17 days ago) | |
US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 2025-12-22
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(a month ago) | |
US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(a month ago) | |
US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(a month ago) | |
US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(a month ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(4 months from now) | |
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(4 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | May 16, 2022 |
Pediatric Exclusivity (PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
Market Authorisation Date: 03 August, 2009
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7458372 | SUNOVION RESP | Inhalation therapy device |
Nov, 2024
(7 months from now) |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(6 months from now) | |
US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 8, 2027 |
New Indication (I) | Mar 11, 2025 |
Drugs and Companies using OLAPARIB ingredient
Market Authorisation Date: 17 August, 2017
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7888328 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(16 days from now) | |
US8785415 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(16 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9101549 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(27 days from now) | |
US7101576 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(27 days from now) | |
US9101540 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(27 days from now) | |
US9107827 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(27 days from now) | |
US9040088 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(27 days from now) |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(6 months from now) |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(a month from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7056500 | REDHILL | Polymer conjugates of opioid antagonists |
Jun, 2024
(3 months from now) | |
US8067431 | REDHILL | Chemically modified small molecules |
Dec, 2024
(8 months from now) |
Drugs and Companies using NALOXEGOL OXALATE ingredient
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169381 | SALIX PHARMS | Colon cleansing compositions and methods |
Sep, 2024
(5 months from now) | |
US7658914 | SALIX PHARMS | Colon cleansing compositions |
Sep, 2024
(5 months from now) |
Market Authorisation Date: 02 August, 2006
Treatment: NA
Dosage: FOR SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7601746 | SHIONOGI INC | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 2022-07-31
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(a month from now) | |
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(a month from now) | |
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(a month from now) | |
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(a month from now) | |
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 months from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8162915 | FRESENIUS KABI USA | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May, 2024
(a month from now) |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 September, 1996
Treatment: NA
Dosage: SOLUTION;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415007 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(4 months from now) | |
US7879349 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(4 months from now) | |
US7229636 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(4 months from now) | |
US8003353 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(4 months from now) |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Supplement for vitamin b12 deficiencies; Cyanocobalamin administration through nasal infusion; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(4 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(4 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7799761 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(6 months from now) |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 2023-08-28
Market Authorisation Date: 27 August, 2019
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(6 months from now) |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 25 August, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(2 months from now) | |
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(2 months from now) |
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2024
(2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 2, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Oct 2, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 2027-10-03
Market Authorisation Date: 02 October, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8517997 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(a month from now) |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: NA
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(a month ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 6, 2026 |
Pediatric Exclusivity (PED) | Mar 6, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jul 27, 2025 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12
Dosage: EMULSION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(a month from now) | |
US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(a month from now) | |
US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(a month from now) | |
US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(a month from now) |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(28 days from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: POWDER;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(4 months from now) |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8394406 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(12 days from now) | |
US8709478 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(12 days from now) | |
US8394405 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(12 days from now) | |
US8470364 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(12 days from now) |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(5 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
New Product (NP) | May 29, 2023 |
NCE-1 date: 2022-07-23
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(5 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 2022-07-23
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2024
(8 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9492443 | ZYLA | Abuse deterrent compositions and methods of making same |
May, 2024
(2 months from now) |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2011
Treatment: NA
Dosage: TABLET;ORAL
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule (D) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 26, 2026 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 2025-02-26
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received a...
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 2025-03-18
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(a month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 5, 2030 |
New Dosing Schedule (D) | Aug 2, 2026 |
New Indication (I) | Jun 5, 2026 |
Drugs and Companies using LETERMOVIR ingredient
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(4 months from now) |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(4 months from now) |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 16 December, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(6 months from now) | |
US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(6 months from now) | |
US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(6 months from now) |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
Dosage: INJECTABLE;INTRATHECAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7736665 | TITAN PHARMS | Implantable polymeric device for sustained release of buprenorphine |
Apr, 2024
(30 days from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Dosage: IMPLANT;IMPLANTATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(6 months from now) | |
US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(6 months from now) | |
US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(6 months from now) |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(2 months from now) |
Drugs and Companies using MODAFINIL ingredient
Market Authorisation Date: 24 December, 1998
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(28 days from now) | |
US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(28 days from now) | |
US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(28 days from now) | |
US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(28 days from now) |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(13 days from now) | |
US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(13 days from now) | |
US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(13 days from now) |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 24 April, 2008
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(8 months from now) | |
US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(8 months from now) | |
US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(8 months from now) |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 21 May, 2002
Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating a human patient suffering...
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) | |
US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) | |
US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) | |
US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) | |
US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) | |
US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(5 months from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 27 December, 2005
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420688 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(4 months from now) |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7531530 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(3 months from now) | |
US7351701 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 6, 2025 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) | |
US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(27 days from now) |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(5 months from now) |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(5 months from now) |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(5 months from now) |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(8 days from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application
Dosage: FILM;BUCCAL, SUBLINGUAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8287489 | ENDO VENTURES LTD | Device for readying a needle free injector for delivery |
Dec, 2024
(8 months from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 15 July, 2009
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(6 months from now) | |
US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(6 months from now) | |
US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(6 months from now) | |
US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(6 months from now) | |
US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(6 months from now) |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(7 months from now) |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8603514 | AQUESTIVE | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(8 days from now) |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: NA
Dosage: FILM;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(a month ago) |
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) | |
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(14 days from now) | |
US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(5 months from now) | |
US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(7 months from now) |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(2 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(2 months from now) | |
US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 13, 2023 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 2022-07-13
Market Authorisation Date: 18 May, 2022
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jan 19, 2030 |
New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
New Indication (I) | Jan 19, 2026 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7294342 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their application |
May, 2024
(a month from now) |
Drugs and Companies using BENZYL ALCOHOL ingredient
Market Authorisation Date: 09 April, 2009
Treatment: Topical treatment of lice infestations
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456207 | TEVA PHARMS | Vaginal pharmaceutical compositions and methods for preparing them |
Sep, 2024
(5 months from now) |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 20 May, 2005
Treatment: NA
Dosage: GEL;VAGINAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(5 months from now) |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 25 November, 2013
Treatment: A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(4 days from now) | |
US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(4 days from now) | |
US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(4 days from now) | |
US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(4 days from now) | |
US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(4 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Oct 2, 2026 |
New Strength (NS) | Oct 2, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
Market Authorisation Date: 21 October, 2015
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 17, 2022 |
Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(8 months from now) |
Drugs and Companies using BOCEPREVIR ingredient
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) | |
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) | |
US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 22 July, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(a month from now) |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
Market Authorisation Date: 25 October, 2013
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(8 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(8 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 3, 2024 |
Orphan Drug Exclusivity (ODE) | May 3, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 2023-05-04
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(8 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(8 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 3, 2024 |
Orphan Drug Exclusivity (ODE) | May 3, 2026 |
Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient
NCE-1 date: 2023-05-04
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2024
(3 months from now) | |
US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2024
(3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 2024-08-26
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(5 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(7 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Dec 20, 2024 |
Pediatric Exclusivity (PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 20 December, 2021
Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...
Dosage: FOR SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9839631 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(3 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9357783 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(3 months from now) | |
US8212038 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 2024-07-24
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8522778 | OPTINOSE US INC | Nasal devices |
Apr, 2024
(25 days from now) |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(2 months from now) | |
US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(2 months from now) | |
US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(2 months from now) | |
US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(2 months from now) | |
US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(2 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(2 months from now) | |
US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(2 months from now) |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(7 months from now) | |
US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(7 months from now) | |
US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(7 months from now) | |
US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(7 months from now) |
Drugs and Companies using LIFITEGRAST ingredient
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7256310 | SUNOVION | Levalbuterol salt |
Oct, 2024
(6 months from now) |
Drugs and Companies using LEVALBUTEROL TARTRATE ingredient
Market Authorisation Date: 11 March, 2005
Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms
Dosage: AEROSOL, METERED;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(2 months from now) | |
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(8 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 26, 2025 |
Pediatric Exclusivity (PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(2 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 9, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 2027-03-10
Market Authorisation Date: 09 March, 2023
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7838531 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2024
(4 months from now) | |
US8828356 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2024
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 20, 2027 |
New Chemical Entity Exclusivity (NCE) | Nov 20, 2025 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 2024-11-20
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7713999 | XSPIRE PHARMA | Thrombin receptor antagonists |
May, 2024
(2 months from now) |
Drugs and Companies using VORAPAXAR SULFATE ingredient
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7012135 | NA | NA |
Feb, 2024
(a month ago) |
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US8227230 | NA | NA |
Feb, 2024
(30 days ago) |
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7217689 | NA | NA |
May, 2024
(a month from now) |
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9795672 | GENENTECH, INC. | Treatment with anti-VEGF antibodies |
May, 2024
(2 months from now) |
Ingredients: BEVACIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7829531 | NA | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Jun, 2024
(2 months from now) |
Ingredients: BRENTUXIMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7759117 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(2 months from now) | |
US7157276 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(2 months from now) |
Ingredients: NATALIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7718175 | NA | Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein |
Jul, 2024
(3 months from now) |
Ingredients: BENRALIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7691378 | NA | NA |
Sep, 2024
(5 months from now) |